BACKGROUND: Signaling by insulin-like growth factor 1 receptor (IGF-1R) can contribute to the formation and progression of many diverse tumor types, including glioblastoma. We investigated the effect of the IGF-1R blocking antibody IMC-A12 on glioblastoma growth in different in vivo models. METHODS: U87 cells were chosen to establish rapidly growing, angiogenesis-dependent tumors in the brains of nude mice, and the GS-12 cell line was used to generate highly invasive tumors. IMC-A12 was administered using convection-enhanced local delivery. Tumor parameters were quantified histologically, and the functional relevance of IGF-1R activation was analyzed in vitro. RESULTS: IMC-A12 treatment inhibited the growth of U87 and GS-12 tumors by 75% and 50%, respectively. In GS-12 tumors, the invasive tumor extension and proliferation rate were significantly reduced by IMC-A12 treatment, while apoptosis was increased. In IMC-A12-treated U87 tumors, intratumoral vascularization was markedly decreased, and tumor cell proliferation was moderately reduced. Flow cytometry showed that <2% of U87 cells but >85% of GS-12 cells expressed IGF-1R. Activation of IGF-1R by IGF-1 and IGF-2 in GS-12 cells was blocked by IMC-A12. Both ligands stimulated GS-12 cell proliferation, and IGF-2 also stimulated migration. IMC-A12 inhibited these stimulatory effects and increased apoptosis. In U87 cells, stimulation with either ligand had no functional effect. CONCLUSIONS: IGF-1R blockade can inhibit glioblastoma growth by different mechanisms, including direct effects on the tumor cells as well as indirect anti-angiogenic effects. Hence, blocking IGF-1R may be useful to target both the highly proliferative, angiogenesis-dependent glioblastoma core component as well as the infiltrative periphery.
BACKGROUND: Signaling by insulin-like growth factor 1 receptor (IGF-1R) can contribute to the formation and progression of many diverse tumor types, including glioblastoma. We investigated the effect of the IGF-1R blocking antibody IMC-A12 on glioblastoma growth in different in vivo models. METHODS:U87 cells were chosen to establish rapidly growing, angiogenesis-dependent tumors in the brains of nude mice, and the GS-12 cell line was used to generate highly invasive tumors. IMC-A12 was administered using convection-enhanced local delivery. Tumor parameters were quantified histologically, and the functional relevance of IGF-1R activation was analyzed in vitro. RESULTS: IMC-A12 treatment inhibited the growth of U87 and GS-12 tumors by 75% and 50%, respectively. In GS-12 tumors, the invasive tumor extension and proliferation rate were significantly reduced by IMC-A12 treatment, while apoptosis was increased. In IMC-A12-treated U87tumors, intratumoral vascularization was markedly decreased, and tumor cell proliferation was moderately reduced. Flow cytometry showed that <2% of U87 cells but >85% of GS-12 cells expressed IGF-1R. Activation of IGF-1R by IGF-1 and IGF-2 in GS-12 cells was blocked by IMC-A12. Both ligands stimulated GS-12 cell proliferation, and IGF-2 also stimulated migration. IMC-A12 inhibited these stimulatory effects and increased apoptosis. In U87 cells, stimulation with either ligand had no functional effect. CONCLUSIONS:IGF-1R blockade can inhibit glioblastoma growth by different mechanisms, including direct effects on the tumor cells as well as indirect anti-angiogenic effects. Hence, blocking IGF-1R may be useful to target both the highly proliferative, angiogenesis-dependent glioblastoma core component as well as the infiltrative periphery.
Authors: Kai-Da Wu; Li Zhou; Douglas Burtrum; Dale L Ludwig; Malcolm A S Moore Journal: Cancer Immunol Immunother Date: 2006-07-11 Impact factor: 6.968
Authors: Per Ø Sakariassen; Lars Prestegarden; Jian Wang; Kai-Ove Skaftnesmo; Rupavathana Mahesparan; Carla Molthoff; Peter Sminia; Eirik Sundlisaeter; Anjan Misra; Berit Bølge Tysnes; Martha Chekenya; Hans Peters; Gabriel Lende; Karl Henning Kalland; Anne M Øyan; Kjell Petersen; Inge Jonassen; Albert van der Kogel; Burt G Feuerstein; A Jorge A Terzis; Rolf Bjerkvig; Per Øyvind Enger Journal: Proc Natl Acad Sci U S A Date: 2006-10-20 Impact factor: 11.205
Authors: Ta-Jen Liu; Tiffany LaFortune; Toshiyuki Honda; Osamu Ohmori; Shinji Hatakeyama; Thomas Meyer; Dowdy Jackson; John de Groot; W K Alfred Yung Journal: Mol Cancer Ther Date: 2007-04 Impact factor: 6.261
Authors: Eric K Rowinsky; Hagop Youssoufian; James R Tonra; Phillip Solomon; Douglas Burtrum; Dale L Ludwig Journal: Clin Cancer Res Date: 2007-09-15 Impact factor: 12.531
Authors: Sarah Löw; Vassilios I Vougioukas; Thomas Hielscher; Ursula Schmidt; Andreas Unterberg; Marc E Halatsch Journal: Anticancer Res Date: 2008 Nov-Dec Impact factor: 2.480
Authors: Joachim P Steinbach; Christine Eisenmann; Andrea Klumpp; Michael Weller Journal: Biochem Biophys Res Commun Date: 2004-08-27 Impact factor: 3.575
Authors: Tobias Martens; Yvonne Laabs; Hauke S Günther; Dirk Kemming; Zhenping Zhu; Larry Witte; Christian Hagel; Manfred Westphal; Katrin Lamszus Journal: Clin Cancer Res Date: 2008-09-01 Impact factor: 12.531
Authors: Liliana Soroceanu; Samir Kharbanda; Ruihuan Chen; Robert H Soriano; Ken Aldape; Anjan Misra; Jiping Zha; William F Forrest; Janice M Nigro; Zora Modrusan; Burt G Feuerstein; Heidi S Phillips Journal: Proc Natl Acad Sci U S A Date: 2007-02-20 Impact factor: 11.205
Authors: C Maris; N D'Haene; A-L Trépant; M Le Mercier; S Sauvage; J Allard; S Rorive; P Demetter; C Decaestecker; I Salmon Journal: Br J Cancer Date: 2015-08-20 Impact factor: 7.640
Authors: Claudia R Oliva; Brian Halloran; Anita B Hjelmeland; Ana Vazquez; Shannon M Bailey; Jann N Sarkaria; Corinne E Griguer Journal: Cell Commun Signal Date: 2018-09-19 Impact factor: 5.712